<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22801223</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2016</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0578-1310</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Zhonghua er ke za zhi = Chinese journal of pediatrics</Title><ISOAbbreviation>Zhonghua Er Ke Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Evaluation of adrenocortical function in children with severe and critical enterovirus 71 infection].</ArticleTitle><Pagination><StartPage>249</StartPage><EndPage>254</EndPage><MedlinePgn>249-54</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the adrenocortical function in children with severe and critical enterovirus 71 infection by using a high-dose (250 &#xb5;g) adrenocorticotropic hormone (ACTH) stimulation test. And to at provide experimental basis for glucocorticoid in the treatment of hand-foot-and-mouth disease (HFMD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This was a prospective multi-center study which was carried out in PICUs of Beijing Children's Hospital, Zhengzhou Children's Hospital, Kaifeng Children's Hospital and Linyi People's Hospital in Shandong province. Children with severe and critical hand-foot-mouth disease admitted to PICUs of the four hospitals from June 2009 to April 2010 were enrolled in this study, and EV71 virus nucleic acid test and high-dose (250 &#xb5;g) ACTH stimulation started at the same time. EV71 virus nucleic acid positive 51 cases were eventually enrolled in the study. Cortisol test was performed at baseline (T0) and after high-dose (250 &#xb5;g) ACTH stimulation at 30 minutes (T30), 60 minutes (T60) in the first 6 hours after admission, but before glucocorticoid was given. The adrenocortical function was evaluated according to &#x394;Tmax [&#x394;Tmax=(T30, T60 maximum)-T0]. Diagnostic criteria of adrenal insufficiency (AI) is increment (&#x394;Tmax)&#x2264;9 &#xb5;g/dl.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">The incidence of AI in 51 cases was 52.94% (27/51). The incidence of AI in severe group was 44.74% (17/38), which was significantly higher in critical group 76.92% (10/13), P&lt;0.05. Of the cases with a pediatric critical illness score (PCIS)&#x2264;70, 81.82% (9/11) had adrenal insufficiency, and it was 28.57% (4/14) when PCIS&#x2265;90. The incidence of AI was 75% (6/8) and 48.84% (21/43) in death and survivor group respectively, but there were no significant difference between the two groups (P&gt;0.05). Baseline (T0) cortisol in death group was higher than survivor group (P&lt;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">AI may occur in children with enterovirus 71 infection. The critical enterovirus 71 infection had a high incidence of AI. AI may affect the prognosis of patients with severe and critical enterovirus 71 infection. Exogenous glucocorticoids administration may be considered when AI is identified or highly suspected. The timing, dosage and regimen of glucocorticoid are still unclear. Further animal experiments and clinical trials are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Center, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yi-bing</ForeName><Initials>YB</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhi-fang</ForeName><Initials>ZF</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yu-fen</ForeName><Initials>YF</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yu-ping</ForeName><Initials>YP</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hui-min</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xing-wang</ForeName><Initials>XW</Initials></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Su-yun</ForeName><Initials>SY</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Er Ke Za Zhi</MedlineTA><NlmUniqueID>0417427</NlmUniqueID><ISSNLinking>0578-1310</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9002-60-2</RegistryNumber><NameOfSubstance UI="D000324">Adrenocorticotropic Hormone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000309" MajorTopicYN="N">Adrenal Insufficiency</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000324" MajorTopicYN="N">Adrenocorticotropic Hormone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22801223</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>